FIRSTANA phase III trial (ClinicalTrials.gov identifier: NCT01308567) assessed whether cabazitaxel is superior to docetaxel in terms of PFS/OS in patients with chemotherapy-naïve mCRPC. PSA ...
Medicare covers one annual prostate-specific antigen (PSA) test for people with prostates if they meet the eligibility guidelines and the test is medically necessary. Medicare typically covers one ...
DEAR DR. ROACH: I am a 68-year old male in good health who exercises regularly, doesn’t take any medications, and doesn’t have a family history of prostate cancer. During my most recent yearly ...
This is a large-scale, population-based, observational study of two screening strategies: annual PSA screening and no screening. We used data from 537,599 US Medicare (2001-2008) beneficiaries age ...
Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...
It follows a recommendation by health experts that only a small group of men should be screened.
In tandem with September’s Prostate Cancer Awareness Month, Cleveland Diagnostics is kicking off a campaign to boost awareness of and education around screening tests for the disease. The flagship ...
A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of ...
Editor’s note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and past president of the Florida Urological Society. Prostate cancer remains a significant concern in my ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results